Live Chat

交易 Vir Biotechnology VIR

出售
 买入

VirBiotechnology 实时图表

5m 15m 30m 1h 4h 1d 1w

金融票据基础知识

Weekly Search
Weekly
Daily
日期 关闭 更改 更改(%)： 开盘价 高 低

最新新闻

Frances Wang 2024 Nov 20, 16:00

MicroStrategy Stock Surges as Bitcoin price rises to fresh record above $94K

Cryptocurrencies
Frances Wang 2024 Nov 20, 16:00

Nasdaq futures decline, Nvidia shares dip following the earnings report

Indices CFD Trading Stocks
Mixed market performance
Neil Wilson 2024 Nov 20, 16:00

Markets Mixed Amid Inflation, Tech Rally, and UK Economic Woes

USD Tech S&P 500
Frances Wang 2024 Nov 19, 16:00

Nvidia shares rallied on AI spending ahead of Nvidia Q3 earnings 2024

NVDA Stocks
Frances Wang 2024 Nov 19, 16:00

Bitcoin price hits record high over $93,800 as Trump rally resumes

Cryptocurrencies
Rising gold prices
Neil Wilson 2024 Nov 19, 16:00

Gold Shines, Bitcoin Surges, and Nvidia Earnings in Focus

Gold Cryptocurrencies
Frances Wang 2024 Nov 18, 16:00

What is the cryptocurrency market doing: Musk's DOGE Role Boosts Dogecoin

Cryptocurrencies
Frances Wang 2024 Nov 18, 16:00

Bitcoin price prediction: BTC May Reach $100K Before New Year

Cryptocurrencies

信息

点差

0.05

点差(%)

0.7429 %

杠杆

1:10

隔夜利息（买入）

-0.0597 %

隔夜利息（卖出）

-0.0292 %

币种

USD

交易时间

市场关闭

星期四

14:31 - 20:59

星期一

14:31-20:59

星期二

14:31-20:59

星期三

14:31-20:59

星期五

14:31-20:59

分析和统计

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

954399552

在外流通股份

137720000

财报日（下一）

0000-00-00

股息收益率

除息日

远期年度股息率

0

远期年股息率

0

每股收益

-3.87

详细了解此金融票据

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

相关金融票据

资产
出售
买入
更改(%)：

立即交易

立即交易

立即交易

立即交易
相关金融票据
Trustpilot
Live Chat